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K e y  M e s s a g e s 
1. Entecavir is a potent antiviral agent against 
hepatitis B virus (HBV). In a cohort of 370 
entecavir-treated chronic hepatitis B patients, 76 
(21%) had a partial virological response, defined 
by detectable HBV DNA at year 1.
2. In HBV reverse transcriptase sequence analysis, 
20 amino acid variants were identified solely in 
the partial responders.
3. There were 4 reverse transcriptase (rt) amino 
acid variants that had significantly different 
distribution between the optimal and partial 
entecavir responders.
4. HBV quasispecies complexity and diversity were 
Identification of hepatitis B virus DNA reverse 
transcriptase variants associated with partial 
response to entecavir
Introduction
Nucleos(t)ide analogues (NA) are potent antiviral 
agents against hepatitis B virus (HBV) infection, 
drastically reducing viral load and improving 
clinical outcome. Lamivudine, adefovir, entecavir, 
telbivudine, and tenofovir are licensed in Hong Kong 
for treatment of chronic hepatitis B. Some patients 
have high HBV DNA, even at the initial stage.1 One 
explanation is that some intrinsic viral properties 
may confer non-responsiveness to a particular 
NA. As the main target of NAs is HBV reverse 
transcriptase (rt), some natural polymorphisms 
in the HBV rt sequences may confer primary non-
responsiveness. 
 HBV in a mixed viral population is known 
as quasispecies. Viral complexity and diversity 
change dynamically during the natural history of 
chronic hepatitis B infection. Studies of their effect 
on response to antiviral agents are rare. This study 
aimed to investigate whether there are some pre-
treatment HBV rt sequence variations that predict 
response to entecavir. In addition, the association 
between quasispecies complexity and diversity and 
entecavir response were evaluated.
Methods
This study was conducted from May 2009 to 
November 2011. Between January 2002 and 
September 2009, 370 chronic hepatitis B patients 
at Queen Mary Hospital underwent daily entecavir 
(0.5 mg) therapy and were followed up for >1 year. 
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None had previously received NA or interferon/
pegylated-interferon therapy. Patients with severe 
liver disease (chronic hepatitis C and autoimmune 
and alcoholic liver disease) were excluded. 
 Patient HBV DNA was measured at baseline 
and year 1 using the COBAS TaqMan HBV Test 
(Roche Diagnostics), with a lower limit and upper 
limit of detection of 60 copies/mL and 6.4 ×108 
copies/mL, respectively. Optimal virological 
response was defined as profound HBV DNA 
suppression to ≤60 copies/mL at the end of the first 
year. Partial virological response was defined as a 
HBV DNA level of >60 copies/mL at year 1. 
 Baseline HBV rt sequence was amplified using 
a High Fidelity Taq Polymerase, followed by DNA 
sequencing. To identify sequence variants present at 
<20% in the viral population, HBV amplicons of the 
partial responders and randomly selected optimal 
responders were subjected to clonal sequencing. 
Differences in the pretreatment DNA polymorphism 
and HBV quasispecies complexity and diversity 
between the optimal and partial responders were 
noted. 
Results
Baseline characteristics
Among the 370 (129 HBeAg-positive and 241 
HBeAg-negative) patients, 76 (21%) exhibited a 
partial virological response to entecavir at year 1. Of 
these partial responders, 41% (53/129) were HBeAg-
positive and 9.5% (23/241) were HBeAg-negative 
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higher in the optimal responders than in the 
partial responders.
5. In multivariate analysis, high baseline HBV DNA, 
hepatitis Be antigen-positivity, and rt variant 
rt124N were significantly associated with partial 
entecavir response.
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(P<0.0001). The gender ratio, baseline alanine 
transaminase (ALT), albumin, and bilirubin levels 
were comparable between the optimal and partial 
responders (Table 1). The mean age was higher in 
the HBeAg-negative optimal responders than partial 
responders (P=0.026). The partial responders had 
a higher baseline HBV DNA level than the optimal 
responders for HBeAg-positive (P<0.001) and 
HBeAg-negative (P=0.001) patients.
HBV rt sequence analysis
HBV rt DNA was successfully amplified by PCR in 
305 patients (114 HBeAg-positive and 191 HBeAg-
negative). Of these, 64 (21%) [47 HBeAg-positive 
and 17 HBeAg-negative] had a partial response to 
entecavir at year 1. For the partial responders, the 
median HBV DNA level at year 1 was 639 copies/
mL (range, 72-2.98×107 copies/mL), and the median 
baseline HBV DNA level was higher than that of the 
optimal responders (HBeAg-positive patients: 8.81 
vs 7.83 log10 copies/mL, P<0.001; HBeAg-negative 
patients: 8.34 vs 6.62 log10 copies/mL, P=0.001).
 Of the 344 amino acid residues in the HBV 
rt region, 217 were conserved among these 305 
patients. Major known drug resistance mutations 
(rtL80I/V, I169T, V173L, L180M, A181V/T, T184G, 
A194T, S202I, M204I/V, N236T, and M250V) 
were not detected, except in one patient in whom 
concomitant rtL80I and rtL180M mutations were 
detected. Twenty amino acid variations (rt7D, rt7N, 
rt12Y, rt18K, rt53I, rt80I, rt118H, rt127W, rt128I, 
rt131S, rt135F, rt139Q, rt153W, rt180M, rt217R, 
TABLE 1.  Baseline characteristics of the optimal and partial entecavir responders
TABLE 2.  Distribution of reverse transcriptase (rt) polymorphisms found exclusively in partial responders receiving entecavir treatment for hepatitis B 
virus (HBV)
Gender Age at baseline 
(years)
Baseline 
HBeAg status
HBV genotype Baseline HBV DNA 
(copies/mL)
Year 1 HBV DNA 
(copies/mL)
rt variations exclusively found 
in partial responders
M 62.9 Positive A >6.4 ×108 5.5 ×105 rt7D + 53I + 139Q + 153W +217R
M 62.3 Negative C 2.3 ×108 3.6 ×102 rt7N
F 53.8 Positive C >6.4 ×108 4.4 ×103 rt12Y
M 22.3 Positive B 1.0 ×108 1.6 ×102 rt18K
M 34.6 Positive C 1.0 ×108 2.4 ×102 rt18K
M 48.2 Positive C 1.1 ×108 2.1 ×102 rt80I + 180M
M 37.1 Negative B 2.2 ×108 8.2 ×101 rt118H
M 28.7 Positive B >6.4 ×108 1.3 ×103 rt127W
M 37.6 Negative B >6.4 ×108 2.7 ×102 rt128I
M 45.7 Positive B >6.4 ×108 2.3 ×102 rt131S
M 31.4 Positive B 1.0 ×108 1.6 ×102 rt135F
M 51.8 Positive C 8.0 ×106 2.1 ×103 rt153W
M 54.8 Negative C 1.5 ×105 8.5 ×101 rt219T
F 52.5 Negative B >6.4 ×108 4.5 ×102 rt233L
F 35.1 Positive C >6.4 ×108 4.5 ×102 rt322I
M 22.0 Positive C 1.0 ×108 5.1 ×104 rt329N
F 39.9 Positive C >6.4 ×108 1.8 ×103 rt336Q
Characteristic HBeAg-positive patients (n=129) HBeAg-negative patients (n=241)
Optimal 
responders 
(n=76)
Partial 
responders 
(n=53)
P value Optimal 
responders 
(n=218)
Partial 
responders 
(n=23)
P value
Mean±SD age (years) 42.6±12.3 40.7±10.8 0.36 51.3±9.3 46.8±8.4 0.026
No. of males:females 55:21 33:20 0.225 147:71 19:4 0.161
Median (range) hepatitis B virus DNA 
(log10 copies/mL)
7.76 (4.40-8.81) 8.81 (5.41-8.81) <0.001 6.43 (3.10-8.81) 7.64 (4.94-8.81) 0.001
Median (range) alanine transaminase (IU/L) 92.5 (12-2019) 107 (20-2144) 0.271 71.5 (11-3000) 93 (38-961) 0.133
Median (range) albumin (g/L) 42 (16-50) 42 (25-48) 0.657 42 (23-51) 42 (30-48) 0.763
Median (range) bilirubin (mmol/L) 14 (6-52) 12 (2-67) 0.162 11 (4-261) 14 (5-216) 0.086
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rt219T, rt233L, rt322I, rt329N, and rt336Q) were 
found exclusively in partial responders. These 
variations were distributed among 17 partial 
responders (Table 2). Variants rt18K and rt153W 
were found in two cases, and all other variants 
were found only once. Due to the rarity, association 
between these polymorphisms and partial/slow 
response was not significantly different and needed 
to be determined by phenotypic assays.
 The distribution of some rt amino acid 
variations differed significantly between optimal 
and partial responders. Specifically, 17 amino 
acid variants were present at a significantly higher 
frequency in 64 partial responders than in the 241 
optimal responders (Table 3). After controlling for 
false discovery during multiple comparisons using 
Bonferroni correction, four rt variants, namely 
rt 53N, rt118N, rt124N, and rt332S, remained to 
have a significantly higher frequency in the partial 
responders than in the optimal responders (Table 3).
 Multivariate analysis was performed to 
determine the independent factors associated with 
partial entecavir response at year 1. All factors with 
significantly different distribution among the partial 
and optimal responders were analysed, namely 
baseline HBeAg status, age, HBV genotype, baseline 
HBV DNA level, rt53N, rt118N, rt124N, and rt332S 
(the four rt variants with differential distribution) 
(Table 3). Multivariate logistic regression analysis 
revealed that high baseline HBV DNA levels 
(P<0.0001, OR=2.30, 95% CI=1.60-3.34), HBeAg-
positivity (P<0.001, OR=3.68, 95% CI=1.79-7.62), 
and rt variant rt124N (P=0.001, OR=3.09, 95% 
CI=1.54-6.18) were independently associated with 
suboptimal entecavir response at year 1.
Minor sequence variations identified by 
clonal sequencing 
Clonal sequencing was performed on the 64 partial 
responders and 34 randomly selected optimal 
responders. Among the polymorphisms found 
exclusively in the partial responders (Table 2), the 
variant rt18K was detected as minor species in 
five additional cases, rt118H was detected in one 
additional case, rt128I in two additional cases, rt131S 
in four additional cases, rt135F in one additional 
case, and rt153W in one additional case.
HBV Quasispecies complexity and diversity
Quasispecies complexity and diversity were 
compared between the optimal and partial 
responders. The optimal responders had a higher 
quasispecies complexity (higher normalised 
Shannon entropy) than the partial responders at 
the nucleotide level (P=0.036) and at the amino 
acid level (P=0.087) [Table 4]. Similarly, the optimal 
responders had a higher quasispecies diversity than 
the partial responders (all P<0.05, Table 4).
Discussion
Entecavir is a potent nucleoside analogue that 
TABLE 3.  Reverse transcriptase (rt) variants with significantly different distribution among partial responders and optimal 
responders
rt variant % of variants found in 
partial responders
% of variants found in 
optimal responders
P value (unadjusted) P value (after 
Bonferroni correction)
rt9H 68.8 53.0 0.025 1
rt16T 50.0 29.6 0.002 0.254
rt53N 51.6 27.4 0.00024 0.031
rt109S 54.7 35.3 0.005 0.635
rt118N 48.4 25.3 0.00034 0.043
rt121I 51.6 29.5 0.001 0.127
rt124N 50.0 23.7 0.000038 0.0048
rt127R 46.9 29.0 0.007 0.889
rt131N 50.0 28.2 0.001 0.127
rt134N 35.9 16.2 0.00048 0.061
rt151Y 51.6 30.3 0.001 0.127
rt221Y 53.1 37.8 0.026 1
rt222A 40.6 21.6 0.002 0.254
rt238H 50.0 31.1 0.005 0.635
rt271M 48.4 26.1 0.001 0.127
rt278V 70.3 54.8 0.025 1
rt332S 43.8 20.1 0.00010 0.013
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suppresses HBV DNA replication. The present study 
showed that 21% of patients still had detectable 
HBV DNA after 1 year of therapy. HBV rt sequence 
analysis of 64 partial responders and 241 optimal 
responders showed that 20 HBV rt variants were 
present exclusively in partial responders. However, 
these variants occurred only in one or two cases, and 
the association was not significant. In addition to the 
20 variants found solely in partial responders, four 
variants were present in a higher proportion in the 
partial responders than in the optimal responders. 
Multivariate analysis showed that high baseline 
HBV DNA, HBeAg-positivity, and the rt variant 
rt124N were independent factors associated with 
slow entecavir response. This is consistent with 
our previous study in which patients with positive 
HBeAg and HBV DNA of >8 log copies/mL had a 
lower rate of HBV DNA undetectability at year 1 
to 3.1 rt124N variant was associated with partial 
entecavir response, even though only 50% of the 
partial responders harboured this variant. Further 
long-term study is needed to demonstrate the 
possible role of rt124N and the variants identified 
solely in the partial responders in susceptibility to 
entecavir.
 Two case reports have identified HBV rt 
variants S219A + Y245H and S246T in entecavir non-
responders.2,3 Phenotypic assays determined that 
the rt variant pattern S219A + Y245H (rather than 
S246T) are associated with a lower susceptibility to 
entecavir in vitro. The present study did not identify 
S219A + Y245H variants. Nevertheless, the findings 
of rt124N and the 20 ‘unique’ variants may provide a 
preliminary identification of putative variant pattern 
of reduced susceptibility to entecavir.
 In the clonal sequencing data, the optimal 
responders had a significantly higher quasispecies 
complexity and diversity than the partial responders. 
It is possible that in the optimal responders a higher 
complexity and diversity was present. There may be 
a ‘less-fit’ subpopulation of viral quasispecies more 
susceptible to entecavir. In contrast, in the partial 
responders, the viral population was less diverse 
and more replication competent, causing a slower 
entecavir response. Further studies using technology 
with a greater sequencing depth (such as ultra-deep 
pyrosequencing or next generation sequencing) are 
needed to further elucidate the association between 
quasispecies complexity/diversity and treatment 
response.
Conclusions
We identified 20 rt variants found exclusively in 
entecavir partial responders and four rt variants 
with significantly different distribution among the 
optimal and partial responders. High baseline HBV 
DNA levels, HBeAg-positivity, and rt124N were 
associated with partial entecavir response at year 
1. The possible association between rt variants and 
entecavir response needs to be proved by in vitro 
phenotypic studies.
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Quasispecies Optimal responders (n=34) Partial responders (n=63) P value
Complexity: normalised Shannon entropy
Mean (range) nucleotide level 0.9673 (0.6868-1) 0.9316 (0.3324-1) 0.036
Mean (range) amino acid level 0.8668 (0.4930-1) 0.7869 (0.2192-1) 0.087
Diversity
Mean (range) genetic distance (nucleotide level) [10-3 substitutions] 8.7083 (3.2747-36.4403) 5.2904 (0.8906-56.1354) 0.019
Mean (range) genetic distance (amino acid level) [10-3 substitutions] 14.0147 (3.3561-66.2545) 8.6151 (0.8923-94.822) 0.032
Mean (range) No. of synonymous substitutions per site (10-3) 12.4076 (3.8811-42.0139) 7.4706 (0.6533-78.0112) 0.015
Mean (range) No. of non-synonymous substitutions per site (10-3) 6.6121 (1.6396-30.8776) 3.9649 (0.4040-43.8353) 0.039
TABLE 4.  Quasispecies complexity and diversity of the entecavir optimal and partial responders
